Logo Prima Biomed

Welcome to the Newsroom

01 June 2017

Prima BioMed Announces Formation of Clinical Advisory Board



SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”) today announced the formation of a Clinical Advisory Board (CAB) to serve as a strategic resource to the company as it continues to advance the clinical development program and commercialisation path for its lead drug candidate IMP321 for cancer patients worldwide.